🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Guangzhou Medical University clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Guangzhou Medical University as lead sponsor. Synced 26 Sep 2026
16Current trials
9Recruiting now
6Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Guangzhou Medical University is the lead sponsor of 16 current clinical trials in our China register. 9 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Pemetrexed, Cadonilimab and Iparomlimab and Tuvonralimab. The most-studied condition is Leptomeningeal Metastasis.

ClinicalTrials.gov trials by status

  • Recruiting956%
  • Not yet open213%
  • Active, closed531%

Trials by phase

  • Observational744%
  • Phase 1/2531%
  • Not applicable319%
  • Phase 216%
01

Clinical trials sponsored by Guangzhou Medical University

16 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis
NCT06809517 · Leptomeningeal Metastasis, Intrathecal Drug Delivery
Phase 1/2 Recruiting 2025-03 China
Second-Generation Laryngeal Mask Airway vs Endotracheal Intubation in Adult Liver Transplantation
NCT07775521 · ClinicalTrials.gov ↗ · Liver Allograft
Not applicable Recruiting 2026-08 China
Peri-operative Nutrition in Infants With Congenital Heart Disease
NCT03626480 · ClinicalTrials.gov ↗ · Congenital Heart Disease
Observational Recruiting 2018-07 China
CLE vs. ROSE for Ex Vivo Lung Biopsy Assessment
NCT07725510 · ClinicalTrials.gov ↗ · Peripheral Pulmonary Lesions (PPLs)
Observational Recruiting 2026-06 China
Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer
NCT06462092 · ClinicalTrials.gov ↗ · Leptomeningeal Metastases
Phase 1/2 Recruiting 2026-01 China
Diagnostic Value of Confocal Laser Endomicroscopy (CelTouch) for Peripheral Lung Lesions
NCT07004946 · ClinicalTrials.gov ↗ · Peripheral Pulmonary Lesion
Observational Recruiting 2025-05 China
Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
NCT06304441 · ClinicalTrials.gov ↗ · Leptomeningeal Metastasis
Not applicable Recruiting 2024-04 China
Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
NCT06296745 · ClinicalTrials.gov ↗ · Leptomeningeal Metastasis
Phase 2 Recruiting 2025-09 China
A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China
NCT06718972 · ClinicalTrials.gov ↗ · Meningeal Metastasis, Non-Small Cell Lung Cancer
Observational Recruiting 2024-09 China
Study on the Effectiveness and Safety of CLE Combined With Cryobiopsy for Diagnosis of Pulmonary Lesions
NCT07352176 · ClinicalTrials.gov ↗ · Pulmonary Lesion, Lung Cancer
Not applicable Not yet open 2026-02 China
A Prospective Clinical Study Observed the Effects of Tubeless Anesthesia Method That Preserves Spontaneous Breathing and the Double-lumen Bronchial Intubation on the Brain Health During the Perioperative Period
NCT07721038 · ClinicalTrials.gov ↗ · Brain Health
Observational Not yet open 2026-07 China
Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
NCT06762080 · ClinicalTrials.gov ↗ · Leptomeningeal Metastasis
Phase 1/2 Active, closed 2025-03 China
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
NCT06809530 · ClinicalTrials.gov ↗ · Leptomeningeal Metastasis, Pemetrexed, PD-1 Inhibitor
Phase 1/2 Active, closed 2025-03 China
AI-Driven Accurate Diagnosis of Pathogens in Severe Pneumonia
NCT07461714 · ClinicalTrials.gov ↗ · Severe Pneumonia
Observational Active, closed 2025-09 China
The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer
NCT07638878 · ClinicalTrials.gov ↗ · Lung Cancer (Locally Advanced or Metastatic)
Observational Active, closed 2020-11 China
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
NCT06462222 · ClinicalTrials.gov ↗ · Leptomeningeal Metastasis
Phase 1/2 Active, closed 2024-06 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Guangzhou Medical University trials

6 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Guangzhou Medical University trials

17 conditions
Leptomeningeal Metastasis6Intrathecal Drug Delivery1Liver Allograft1Congenital Heart Disease1Peripheral Pulmonary Lesions (PPLs)1Leptomeningeal Metastases1Peripheral Pulmonary Lesion1Pemetrexed1PD-1 Inhibitor1CTLA41Meningeal Metastasis1Non-Small Cell Lung Cancer1Severe Pneumonia1Pulmonary Lesion1Lung Cancer1Brain Health1Lung Cancer (Locally Advanced or Metastatic)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China169

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Leptomeningeal Metastasis

SponsorTrials
Cerenome2
Shanghai Cancer Hospital, China1

Sponsors with the most current trials registered for this condition.

06

Questions about Guangzhou Medical University trials

How many clinical trials does Guangzhou Medical University sponsor?

Guangzhou Medical University is the lead sponsor of 16 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Guangzhou Medical University trials recruiting?

Yes. 9 of its 16 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Guangzhou Medical University testing?

Its current trials name 6 drugs and biologicals as interventions. The most frequent are Pemetrexed (6), Cadonilimab (1), Iparomlimab and Tuvonralimab (1), Ivonescimab (1) and Osimertinib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.